Superworth

Gilead Sciences EV/EBIT GILD

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2010.

Today, Nov 3, 2026
24.6×
10-year median
10.2×
Against its 10-year history
100th
percentile: 0 is its lowest day, 100 its highest
10-year range
5.3× to 24.6×
Peer median
27.5×

Gilead Sciences' EV/EBIT is 24.6× as of Nov 3, 2026.

That is above its ten-year median of 10.2×, higher than on 100% of days in the last ten years.

Over that time it ranged from 5.3× in Feb 2017 to 24.6× in Oct 2026.

The median for 8 large drugmakers of a similar size is 27.5×.

EV/EBIT over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far24.6×15.9×24.6×
202516.3×13.6×17.4×
202414.2×11.8×15.4×
202314.4×11.5×14.4×
202213.2×8.4×13.6×
20219.6×8.9×10.9×
20208.6×8.4×11.6×
20199.2×8.3×9.6×
20188.5×6.1×9.8×
20175.9×5.3×7.0×
20165.6×5.3×7.0×
20157.3×7.2×13.4×
201411.9×11.9×29.7×
201326.9×16.6×27.0×
201216.0×7.7×16.7×
20117.4×6.6×8.3×
20106.7×6.5×8.3×

Against its peers

Companies in Drug Manufacturers - General nearest Gilead Sciences' size, closest first, today.

CompanyEV/EBIT
GILDGilead Sciences24.6×
AMGNAmgen25.8×
PFEPfizer14.7×
BMYBristol-Myers Squibbn/m
MRKMerckn/m
ABBVAbbVie27.5×
JNJJohnson & Johnsonn/m
BIIBBiogen39.2×
LLYEli Lilly and35.1×
Peer median27.5×

Where Gilead Sciences ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Gilead Sciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.